Small molecules for modulating protein driven liquid-liquid phase separation in treating neurodegenerative disease
Wheeler RJ., Lee HO., Poser I., Pal A., Doeleman T., Kishigami S., Kour S., Anderson EN., Marrone L., Murthy AC., Jahnel M., Zhang X., Boczek E., Fritsch A., Fawzi NL., Sterneckert J., Pandey U., David DC., Davis BG., Baldwin AJ., Hermann A., Bickle M., Alberti S., Hyman AA.
AbstractAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with few avenues for treatment. Many proteins implicated in ALS associate with stress granules, which are examples of liquid-like compartments formed by phase separation. Aberrant phase transition of stress granules has been implicated in disease, suggesting that modulation of phase transitions could be a possible therapeutic route. Here, we combine cell-based and protein-based screens to show that lipoamide, and its related compound lipoic acid, reduce the propensity of stress granule proteins to aggregate in vitro. More significantly, they also prevented aggregation of proteins over the life time of Caenorhabditis elegans. Observations that they prevent dieback of ALS patient-derived (FUS mutant) motor neuron axons in culture and recover motor defects in Drosophila melanogaster expressing FUS mutants suggest plausibility as effective therapeutics. Our results suggest that altering phase behaviour of stress granule proteins in the cytoplasm could be a novel route to treat ALS.